Modality
ADC
MOA
SGLT2i
Target
APOC3
Pathway
Cell Cycle
Breast CaLN
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
→ Jul 2028
Phase 1Current
NCT08881430
2,294 pts·LN
2020-06→2028-07·Terminated
2,294 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-242.3y awayPh2 Data· LN
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2028-07-24 · 2.3y away
LN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08881430 | Phase 1/2 | LN | Terminated | 2294 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |